Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

NCT04214288 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04214288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04214288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 22, 2020
Completion date
June 16, 2027
Enrollment
240 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

advanced er-positive her2-negative breast cancer